FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2094804958> ?p ?o ?g. }

• W2094804958 endingPage "1052" @default.
• W2094804958 startingPage "1043" @default.
• W2094804958 abstract "Prostate-specific antigen (PSA) is extensively used in case selection and outcome evaluation after treatment of clinically localized prostate cancer. Careful case selection can have a profound impact on pathologic findings and ultimate outcome. In addition, salvage treatment is frequently initiated at the time of biochemical relapse rather than clinical recurrence. Consequently, patterns of failure can be significantly altered compared to previous times when PSA was not available. To better understand the impact of PSA on pathologic findings, outcome, and salvage treatment, we reviewed our experience in the PSA era with clinical Stage T1-2 prostate cancer treated with radical prostatectomy.Between 1987 and 1993, 423 cases could be identified with clinical Stage T1-2 prostate cancer treated with radical prostatectomy. The distribution of cases by pretreatment PSA levels was as follows: < or = 4 ng/ml (18%), 4-10 ng/ml (42%), 10-20 ng/ml (21%), > 20 ng/ml (14%), and unknown (5%). The median pretreatment PSA level for the entire group was 8.0 ng/ml. Sixteen patients received adjuvant or neoadjuvant androgen suppression and 13 received postoperative radiotherapy. Only 31 patients (7%) had pathologically positive pelvic lymph nodes. The overall margin involvement rate was 46%. Fifty-three percent of patients had surgical Gleason scores > or = 7, and 65% had extracapsular extension. The median follow-up time was 41 months.The projected overall survival at 7 years after surgery was 90%. The 5-year clinical relapse-free survival rate was 84%. At 5 years, the local control and distant failure rates were 92% and 91%, respectively. Biochemical relapse was defined as a detectable or rising PSA level after prostatectomy. The 5-year biochemical relapse-free survival (bRFS) rate was 59%. The 5-year RFS was 88% in patients with preoperative PSA levels < or = 4, 62% for 4-10, 48% for 10-20, and 31% for > 20. Combining the two independent preoperative variables, iPSA and biopsy GS (bGS), two risks groups were defined: low risk [initial PSA (iPSA) levels < or = 10.0 and bGS < or = 6] and high risk (iPSA levels > 10.0 ng/ml or bGS > or = 7). The 5-year bRFS rate for the low-risk cases was 81% vs. 40% for high-risk cases (p < 0.001). On multivariate analysis, three factors independently predicted biochemical relapse: iPSA levels (p = 0.005), Gleason score from the surgical specimen (sGS) (p = 0.002), and positive surgical margins (p < or = 0.001). The 5-year bRFS rates for margin positive vs. margin negative patients were 37% vs. 78%, respectively. The 5-year bRFS rates for GS > or = 7 vs. GS > or = 6 were 42% vs. 80%, respectively. All clinical relapses were accompanied by a rise in PSA. In patients who manifested biochemical failure followed by a clinical failure, the median interval between the PSA rise and clinical failure was 19 months (range 7-71). Margin involvement was the only independent predictor of local failure (p = 0.019). The 5-year local failure-free survival for negative margin cases was 96% vs. 87% for positive margin cases (p = 0.012). Lymph node (LN) involvement and high-risk group were the two independent predictors of distant failure. The 5-year distant failure-free survival for negative LN cases was 94% vs. 67% for positive LN cases (p < 0.001). The 5-year distant failure-free survival for low-risk cases was 97% vs. 85% for high-risk cases (p = 0.005). For the 124 patients failing biochemically, 85 were observed and 39 were treated either with radiation or androgen deprivation. With a median follow-up of 32 months, the clinical disease relapse-free survival was 79% for the treated patients vs. only 32% for the patients observed (p < 0.001).Pretreatment PSA is the most potent clinical factor independently predicting biochemical relapse, thereby allowing markedly better case selection. Achieving negative margins, even in relatively advanced disease, provides excellent lon" @default.
• W2094804958 created "2016-06-24" @default.
• W2094804958 creator A5001069772 @default.
• W2094804958 creator A5024098067 @default.
• W2094804958 creator A5038790327 @default.
• W2094804958 creator A5081391086 @default.
• W2094804958 date "1997-03-01" @default.
• W2094804958 modified "2023-09-28" @default.
• W2094804958 title "State T1–2 prostate cancer: A multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy" @default.
• W2094804958 cites W1414585854 @default.
• W2094804958 cites W165132104 @default.
• W2094804958 cites W190857994 @default.
• W2094804958 cites W1921045897 @default.
• W2094804958 cites W1978267162 @default.
• W2094804958 cites W1986356842 @default.
• W2094804958 cites W2000979583 @default.
• W2094804958 cites W2050318104 @default.
• W2094804958 cites W2051236771 @default.
• W2094804958 cites W2053510778 @default.
• W2094804958 cites W2054845998 @default.
• W2094804958 cites W2127095751 @default.
• W2094804958 cites W2222589758 @default.
• W2094804958 cites W2312408681 @default.
• W2094804958 cites W2397717046 @default.
• W2094804958 cites W2399030910 @default.
• W2094804958 cites W2402217318 @default.
• W2094804958 cites W2408870408 @default.
• W2094804958 cites W2410181980 @default.
• W2094804958 cites W27466347 @default.
• W2094804958 cites W4293658047 @default.
• W2094804958 cites W58289321 @default.
• W2094804958 doi "https://doi.org/10.1016/s0360-3016(96)00590-1" @default.
• W2094804958 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9169811" @default.
• W2094804958 hasPublicationYear "1997" @default.
• W2094804958 type Work @default.
• W2094804958 sameAs 2094804958 @default.
• W2094804958 citedByCount "204" @default.
• W2094804958 countsByYear W20948049582012 @default.
• W2094804958 countsByYear W20948049582013 @default.
• W2094804958 countsByYear W20948049582014 @default.
• W2094804958 countsByYear W20948049582015 @default.
• W2094804958 countsByYear W20948049582016 @default.
• W2094804958 countsByYear W20948049582017 @default.
• W2094804958 countsByYear W20948049582018 @default.
• W2094804958 countsByYear W20948049582019 @default.
• W2094804958 countsByYear W20948049582020 @default.
• W2094804958 countsByYear W20948049582021 @default.
• W2094804958 countsByYear W20948049582023 @default.
• W2094804958 crossrefType "journal-article" @default.
• W2094804958 hasAuthorship W2094804958A5001069772 @default.
• W2094804958 hasAuthorship W2094804958A5024098067 @default.
• W2094804958 hasAuthorship W2094804958A5038790327 @default.
• W2094804958 hasAuthorship W2094804958A5081391086 @default.
• W2094804958 hasConcept C121608353 @default.
• W2094804958 hasConcept C126322002 @default.
• W2094804958 hasConcept C126894567 @default.
• W2094804958 hasConcept C141071460 @default.
• W2094804958 hasConcept C143998085 @default.
• W2094804958 hasConcept C146357865 @default.
• W2094804958 hasConcept C151730666 @default.
• W2094804958 hasConcept C2776235491 @default.
• W2094804958 hasConcept C2777008409 @default.
• W2094804958 hasConcept C2778913397 @default.
• W2094804958 hasConcept C2779466945 @default.
• W2094804958 hasConcept C2780192828 @default.
• W2094804958 hasConcept C2780849966 @default.
• W2094804958 hasConcept C2781406297 @default.
• W2094804958 hasConcept C509974204 @default.
• W2094804958 hasConcept C71924100 @default.
• W2094804958 hasConcept C86803240 @default.
• W2094804958 hasConceptScore W2094804958C121608353 @default.
• W2094804958 hasConceptScore W2094804958C126322002 @default.
• W2094804958 hasConceptScore W2094804958C126894567 @default.
• W2094804958 hasConceptScore W2094804958C141071460 @default.
• W2094804958 hasConceptScore W2094804958C143998085 @default.
• W2094804958 hasConceptScore W2094804958C146357865 @default.
• W2094804958 hasConceptScore W2094804958C151730666 @default.
• W2094804958 hasConceptScore W2094804958C2776235491 @default.
• W2094804958 hasConceptScore W2094804958C2777008409 @default.
• W2094804958 hasConceptScore W2094804958C2778913397 @default.
• W2094804958 hasConceptScore W2094804958C2779466945 @default.
• W2094804958 hasConceptScore W2094804958C2780192828 @default.
• W2094804958 hasConceptScore W2094804958C2780849966 @default.
• W2094804958 hasConceptScore W2094804958C2781406297 @default.
• W2094804958 hasConceptScore W2094804958C509974204 @default.
• W2094804958 hasConceptScore W2094804958C71924100 @default.
• W2094804958 hasConceptScore W2094804958C86803240 @default.
• W2094804958 hasIssue "5" @default.
• W2094804958 hasLocation W20948049581 @default.
• W2094804958 hasLocation W20948049582 @default.
• W2094804958 hasOpenAccess W2094804958 @default.
• W2094804958 hasPrimaryLocation W20948049581 @default.
• W2094804958 hasRelatedWork W1533661207 @default.
• W2094804958 hasRelatedWork W1967410728 @default.
• W2094804958 hasRelatedWork W2101697404 @default.
• W2094804958 hasRelatedWork W2143318777 @default.
• W2094804958 hasRelatedWork W2898356416 @default.
• W2094804958 hasRelatedWork W2933433809 @default.

• next